AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01537796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT weight loss
Description: Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
Study NCT01090687 — intervention group
Intervention type: RADIATION
Intervention: computed tomography (CT scan)
Description: Subjects will undergo cone beam breast CT scan
Study NCT01537796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT-BT weight loss
Description: Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
Study NCT01090687 — intervention group
Intervention type: DEVICE
Intervention: computed tomography (CT scan)
Description: Subjects will undergo cone beam breast CT scan
Study NCT03899077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use
Study NCT03899077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial
Description: Leuprorelin acetate 45mg for 6 months; subcutaneous use
Study NCT03899077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate 10.8 MG Subcutaneous Implant
Description: Goserelin acetate 10.8mg for 6 months; subcutaneous use
Study NCT03899077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin Pamoate
Description: Triptorelin pamoate 22.5mg for 6 months; intramuscular use
Study NCT03899077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix acetate
Description: Degarelix acetate 80mg for 6 months; subcutaneous use
Study NCT03612440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
Study NCT03612440 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: receive matching placebo (equal volum of normal saline)
Study NCT03353896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wear novoTTF-200A
Description: Wear novoTTF-200A device
Study NCT03353896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02753231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low physical activity program
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Study NCT02753231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High physical activity program
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Study NCT02753231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low and High physical activity program
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Study NCT02397499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02027805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Guard
Study NCT02753231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical activity program
Description: One Physical Education sessions / week
Study NCT00395694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamictal
Description: anti-epileptic drug
Study NCT00185458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG IUS
Description: LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
Study NCT01395563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Description: strength training, high intensity, twice up to 3 times per week
Study NCT01871662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Legalon® SIL (Silibinin)
Description: Silibinin 20 mg/Kg/day
Study NCT01871662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa2b
Description: 1.5 µg/kg once-weekly
Study NCT01871662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa2b
Description: 1.5 µg/kg once-weekly
Study NCT01871662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: At weight-based dose 800-1400 mg/day (BID, OS)
Study NCT02643784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.
Study NCT01029301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: EndyMed Pro System for Skin Tightening
Description: Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);
Study NCT01871662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: At weight-based dose 800-1400 mg/day (BID, OS)
Study NCT02627235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIAL
Description: The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.
Study NCT02627235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait List Control
Description: Access to DIAL intervention 12 weeks following baseline assessment.
Study NCT03530852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relizorb
Description: Tube feeds run across device to digest fats.
Study NCT03930563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-beetroot juice supplementation
Description: Before administering beetroot juice to subjects.
Study NCT03930563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-beetroot juice supplementation
Description: Before administering beetroot juice to subjects.
Study NCT03930563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-beetroot juice supplementation
Description: After administering beetroot juice to subjects.
Study NCT03930563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post-beetroot juice supplementation
Description: After administering beetroot juice to subjects.
Study NCT01713764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet
Study NCT01713764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: American Diabetes Association Diet
Study NCT01713764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness and Positive Affect Skills
Study NCT01713764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Positive Affect Skills
Study NCT01669330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nissen fundoplication
Description: Laparoscopic Nissen fundoplication
Study NCT01669330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic antireflux surgery ad modum Watson
Description: Laparoscopic anterior fundoplication
Study NCT02643784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.
Study NCT00860925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active clonidine
Description: Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
Study NCT04941625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum cystatin C
Description: blood sampling
Study NCT04941625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum beta-microglubulin
Description: blood sampling
Study NCT04941625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urine
Description: neutrophil gelatinase-associated lipocalin
Study NCT04611672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of CA
Description: As part of our routine stroke work up, each patient receives an initial CT scan with CT perfusion to indicate thrombolysis therapy (intravenous, mechanical, or both, depending on the time since first stroke symptoms and perfusion-mismatch), an MRI within 2 days, extracranial and transcranial Duplex ultrasound, echocardiography, continuous Monitoring of BP, O2, body temperature, NIHSS and Glagow Coma Scale (GCS) every 6 hours. Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
Study NCT04611672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assesment of CA only
Description: Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
Study NCT02349932 — intervention group
Intervention type: OTHER
Intervention: Healthy Adults
Description: The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
Study NCT03958565 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tyrosine Kinase Inhibitor
Description: Targeted therapy given as standard of care.
Study NCT03958565 — intervention group
Intervention type: DRUG
Intervention: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
Description: Given Q4 weeks as standard of care
Study NCT00860925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active ASA
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
Study NCT01655966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D +pegylated interferon + ribavirin
Description: Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
Study NCT01655966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon + ribavirin
Description: pegylated interferon 160ug once weekly Ribavirin (> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
Study NCT03873857 — intervention group
Intervention type: DRUG
Intervention: Venetoclax
Description: tablet;oral
Study NCT01481441 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SonoVue
Description: 2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
Study NCT05420350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine and Bupropion
Description: Lamotrigine-oral pill taken once or twice a day with varying dosage per study timeline Bupropion-oral pill 100mg taken twice a day
Study NCT05420350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral pill matched with lamotrigine to be taken once or twice a day per study timeline Oral pill matched with bupropion to be taken twice a day
Study NCT00860925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine Placebo
Description: Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
Study NCT00860925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Placebo
Description: Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
Study NCT00860925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA Placebo
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
Study NCT00860925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA Placebo
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
Study NCT02140827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMP interactive education
Description: The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
Study NCT03315364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral paclitaxel
Description: Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Study NCT03315364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Study NCT00361153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam hydrochloride
Description: Welchol tablet 625mg
Study NCT00361153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01908842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNX sublingual tablets
Description: Buprenorphine/naloxone sublingual tablets
Study NCT01908842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNX sublingual tablets
Description: Buprenorphine/naloxone sublingual tablets
Study NCT01908842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNX sublingual film
Description: Buprenorphine/naloxone sublingual film
Study NCT01908842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNX sublingual film
Description: Buprenorphine/naloxone sublingual film
Study NCT01908842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine sublingual tablets
Study NCT02568423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab - IV
Description: Administered IV
Study NCT02568423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab - SC
Description: Administered SC
Study NCT02568423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV
Study NCT02568423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study NCT01379209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGI-2001
Description: A single administration of RGI-2001 on Day 0 post AHSCT.
Study NCT01379209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin Inhibitors
Description: GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Study NCT01379209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: According to institutional guidelines.
Study NCT01379209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Study NCT03958565 — intervention group
Intervention type: DRUG
Intervention: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Description: Given Q12 weeks for bone disease as standard of care
Study NCT02138799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: oral
Study NCT02138799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: oral
Study NCT00950339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole, 20mg twice daily
Description: Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity
Study NCT00950339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine 40mg twice daily
Description: Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity
Study NCT00950339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole 40mg once daily
Description: Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity
Study NCT01593267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coil embolization
Description: Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
Study NCT00460993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lunesta
Description: Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4.
Study NCT00664170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX-514
Description: 75 mg/m\^2
Study NCT01593267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clip occlusion
Description: Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
Study NCT02621684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Activities Model Program for Seniors (CHAMPS)
Description: * Physical activity questionnaire for older adults~* Asks about activities in the past 4 weeks~* 41 questions and asks to notate how long the activity took
Study NCT02621684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Activities Model Program for Seniors (CHAMPS)
Description: * Physical activity questionnaire for older adults~* Asks about activities in the past 4 weeks~* 41 questions and asks to notate how long the activity took
Study NCT02621684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifetime Total Physical Activity Questionnaire
Description: * Questions about leisure time (27) and household activities (5)~* Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years